MK-3207_Hydrochloride_LCMS_09535_MedChemExpress

=====================================================================Acq. Operator : Li Shan(LCMS-02) Seq. Line : 68Acq. Instrument : HY-LCMS-02 Location : P1-C-03Injection Date : 5/22/2015 5:29:04 PM Inj : 1Inj Volume : 3.000 µlAcq. Method : D:\AGLIENT 1260\DATA\20150522\20150522 2015-05-22 09-03-34\100-1000MS+3MIN- 1.5_(0.02%FA).MLast changed : 5/22/2015 9:03:35 AM by Li Shan(LCMS-02)Analysis Method : D:\AGLIENT 1260\METHOD\100-1000MS+3MIN-1.5_(0.02%FA).M Last changed : 5/25/2015 9:54:31 AM by Li Shan(LCMS-02) (modified after loading)Method Info : Postive,MS:100-1000,Column ID:A-RP-132,40℃Catalog No : HY-13032 Batch#09995 A-RP-132Additional Info : Peak(s) manually integratedmin0.511.52 2.53mAU 020040060080010001200 DAD1 B, Sig=214,4 Ref=off (D:\AGLIENT...0\DATA\20150522\20150522 2015-05-22 09-03-34\CPK2015-522-09995.D)1.7321.8922.1262.272===================================================================== Area Percent Report =====================================================================Sorted By : Signal Multiplier : 1.0000Dilution : 1.0000Do not use Multiplier & Dilution Factor with ISTDsSignal 1: DAD1 B, Sig=214,4 Ref=offPeak RetTime Type Width Area Height Area # [min] [min] [mAU*s] [mAU] %----|-------|----|-------|----------|----------|--------| 1 1.732 MM 0.0766 21.21166 4.61753 0.4572 2 1.892 MM 0.0550 4601.70752 1395.56250 99.1956 3 2.126 MM 0.0656 4.72814 1.20124 0.1019 4 2.272 MM 0.0979 11.37471 1.93734 0.2452Totals : 4639.02203 1403.31860===================================================================== *** End of Report ***============================================================Acq. Operator : Li Shan(LCMS-02) Seq. Line : 68Acq. Instrument : HY-LCMS-02 Location : P1-C-03Injection Date : 5/22/2015 5:29:04 PM Inj : 1Inj Volume : 3.000 µlAcq. Method : D:\AGLIENT 1260\DATA\20150522\20150522 2015-05-22 09-03-34\100-1000MS+3MIN- 1.5_(0.02%FA).MLast changed : 5/22/2015 9:03:35 AM by Li Shan(LCMS-02)Analysis Method : D:\AGLIENT 1260\METHOD\100-1000MS+3MIN-1.5_(0.02%FA).M Last changed : 5/25/2015 9:55:45 AM by Li Shan(LCMS-02) (modified after loading)Method Info : Postive,MS:100-1000,Column ID:A-RP-132,40℃Catalog No : HY-13032 Batch#09995 A-RP-132Additional Info : Peak(s) manually integratedmin0.511.52 2.53050000100000150000200000250000 MSD1 TIC, MS File (D:\AGLIENT 1260\DATA\20150522\20150522 2015-05-22 09-03-34\CPK2015-522-09995.D) ES-API, Pos, Sc1.882MS Signal: MSD1 TIC, MS File, ES-API, Pos, Scan, Frag: 50 Spectra averaged over upper half of peaks. Noise Cutoff: 1000 counts.Reportable Ion Abundance: > 10%.Retention Mol. Weight Time (MS) MS Area or Ion1.882 1300303 869.30 I 426.10 I 425.10 I 424.10 I 212.60 Im/z2004006008001000020406080100*MSD1 SPC, time=1.853:1.908 of D:\AGLIENT 1260\DATA\20150522\20150522 2015-05-22 09-03-34\CPK2015-522-09995.D ES-API Max: 92308213.3 870.3212.6425.1427.1424.1*** End of Report ***。

矿产资源开发利用方案编写内容要求及审查大纲
矿产资源开发利用方案编写内容要求及《矿产资源开发利用方案》审查大纲一、概述
㈠矿区位置、隶属关系和企业性质。

如为改扩建矿山, 应说明矿山现状、
特点及存在的主要问题。

㈡编制依据
(1简述项目前期工作进展情况及与有关方面对项目的意向性协议情况。

(2 列出开发利用方案编制所依据的主要基础性资料的名称。

如经储量管理部门认定的矿区地质勘探报告、选矿试验报告、加工利用试验报告、工程地质初评资料、矿区水文资料和供水资料等。

对改、扩建矿山应有生产实际资料, 如矿山总平面现状图、矿床开拓系统图、采场现状图和主要采选设备清单等。

二、矿产品需求现状和预测
㈠该矿产在国内需求情况和市场供应情况
1、矿产品现状及加工利用趋向。

2、国内近、远期的需求量及主要销向预测。

㈡产品价格分析
1、国内矿产品价格现状。

2、矿产品价格稳定性及变化趋势。

三、矿产资源概况
㈠矿区总体概况
1、矿区总体规划情况。

2、矿区矿产资源概况。

3、该设计与矿区总体开发的关系。

㈡该设计项目的资源概况
1、矿床地质及构造特征。

2、矿床开采技术条件及水文地质条件。

Inhibitors, Agonists, Screening Librarieswww.MedChemExpress.com

Certificate of Analysis

PHYSICAL AND CHEMICAL PROPERTIES 

Molecular Formula:C15H12I3NO4

Molecular Weight:650.97

Storage:Powder-20°C3 years4°C2 yearsIn solvent-80°C6 months-20°C1 monthChemical Structure:

ANALYTICAL DATA 

Appearance:White to off-white (Solid)1 H NMR Spectrum:Consistent with structureLCMS:Consistent with structurePurity (LCMS):99.23%Conclusion:The product has been tested and complies with the given specifications.

Product Name:3,3',5-Triiodo-L-thyronineCat. No.:HY-A0070ACAS No.:6893-02-3Batch No.:16053Chemical Name:L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-

Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.comAddress: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Inhibitors, Agonists, Screening Librarieswww.MedChemExpress.com

Certificate of Analysis

PHYSICAL AND CHEMICAL PROPERTIES 

Molecular Formula:C32H41N5O10

Molecular Weight:655.70

Storage:Powder-20°C3 years4°C2 yearsIn solvent-80°C6 months-20°C1 monthChemical Structure:

ANALYTICAL DATA 

Appearance:White to off-white (Solid)1 H NMR Spectrum:Consistent with structureLCMS:Consistent with structurePurity (LCMS):98.01%Conclusion:The product has been tested and complies with the given specifications.

Product Name:Capromorelin (Tartrate)Cat. No.:HY-15243CAS No.:193273-69-7Batch No.:25157Chemical Name:Propanamide, 2-amino-N-[(1R)-2-[(3aR)-2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-5H-pyrazolo[4,3-c]pyridin-5-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl-, (2R,3R)-2,3-

dihydroxybutanedioate (1:1)

Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.comAddress: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA